1. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
- Author
-
Machherndl-Spandl, Sigrid, Vockenhuber, Thomas, Binder, Michaela, Weltermann, Ansgar, Apfalter, Petra, Lass-Flörl, Cornelia, and Girschikofsky, Michael
- Subjects
- *
ACUTE myeloid leukemia , *MYCOSES , *VORICONAZOLE , *INDUCTION chemotherapy , *PREVENTIVE medicine - Abstract
Invasive fungal infections (IFIs) are commonly observed in patients, who are at high risk of severe infections during the neutropenic phase. The aim of this retrospective single-center study was to evaluate the efficacy and safety of voriconazole as a fungal prophylaxis after induction chemotherapy for acute myeloid leukemia (AML) in adult patients. Six proven/probable IFIs were diagnosed in 213 patients with AML (median age 61 years, range 18–85), who received a total of 377 induction chemotherapies. This yielded an incidence rate of 1.6% based on all induction cycles administered. Voriconazole prophylaxis was administered as intended in 317 out of 377 (84%) induction cycles until the end of neutropenia with a median duration of 20 days (range: 2–101 days). In conclusion, voriconazole demonstrates efficacy and safety as a first-line IFI prophylaxis comparable to published data on posaconazole, which is the standard fungal prophylaxis recommendation for AML patients in international guidelines today. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF